Skeletal muscle loss during anti-epidermal growth factor receptor therapy is an independent prognostic factor on non-small cell lung cancer patients survival

Basit Öğe Kaydı
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.authorwosidKüçükarda, Ahmet/AGF-2120-2022
dc.authorwosidKurt, Nazmi/JFA-8132-2023
dc.contributor.authorKucukarda, Ahmet
dc.contributor.authorGokyer, Ali
dc.contributor.authorGokmen, Ivo
dc.contributor.authorHacioglu, Muhammed Bekir
dc.contributor.authorKostek, Osman
dc.contributor.authorKurt, Nazmi
dc.contributor.authorKarabulut, Derya
dc.date.accessioned2024-06-12T11:14:11Z
dc.date.available2024-06-12T11:14:11Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose: We aimed to assess whether skeletal muscle loss during EGFR thyrosine kinase inhibitor therapy of advance non-small cell lung cancer patients is an independent prognostic factor for progression-free survival (PFS) and overal survival (OS). Methods: A total of 45 patients who had computed tomography images were retrospectively evaluated at the diagnosis and during the treatment period before progression occurs. Results: During treatment 19 patients (42.2%) had skeletal muscle loss. Objective response rates in muscle loss group and muscle stable group were 36.8% and 73.0%, respectively (p<0.01). Median follow-up time was 18.9 months (14.832.1). Median PFS was 14.7 months (95% CI 12.1-17.3) in muscle stable group and 7.6 months (95% CI 6.7-8.5) in muscle loss group (p<0.01). Median OS was 18.3 months (95% CI 16.5-20.2) in muscle loss group while it was 30.1 months (95% CI 22.1-38.2) in muscle stable group (p<0.01). In multivariate analysis for both PFS and OS, skeletal muscle loss was an independent prognostic factor. Hazard ratios (HR) for PFS and OS were 12.2 (95% CI 4.3-34.4) and 3.51 (95% CI 1.41-8.73) respectively. Conclusion: On CT imaging skeletal muscle loss before progression is an independent prognostic factor for both PFS and OS in advance non-small cell lung cancer patients who received EGFR tyrosine kinase inhibitor therapy.en_US
dc.identifier.endpage860en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue3en_US
dc.identifier.pmid34268945en_US
dc.identifier.scopus2-s2.0-85109711578en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage853en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23834
dc.identifier.volume26en_US
dc.identifier.wosWOS:000668815400030en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal Of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSkeletal Muscle Massen_US
dc.subjectEGFR Tyrosine Kinaseen_US
dc.subjectMetastatic Non-Small Cell Lung Canceren_US
dc.subjectPrognosisen_US
dc.subjectBody-Mass Indexen_US
dc.subjectPhase-Iiien_US
dc.subjectOpen-Labelen_US
dc.subject1st-Line Treatmenten_US
dc.subjectEgfren_US
dc.subjectMutationsen_US
dc.subjectSarcopeniaen_US
dc.subjectErlotiniben_US
dc.subjectChemotherapyen_US
dc.subjectGefitiniben_US
dc.titleSkeletal muscle loss during anti-epidermal growth factor receptor therapy is an independent prognostic factor on non-small cell lung cancer patients survivalen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu